Eli Lilly and Company (NYSE: LLY), a global healthcare and biopharmaceutical company, announced on Tuesday that it is constructing a new pharmaceutical manufacturing facility in North Carolina's Research Triangle Park.
The company said it will invest over USD470m in this state-of-the-art facility that will produce parenteral (or injectable) products and delivery devices. In addition, Lilly will create more than 400 jobs in highly skilled positions such as scientists, engineers, quality professionals and manufacturing operations.
"Life science companies like Lilly continue to choose North Carolina," said Roy Cooper, Governor of North Carolina. "Our exceptional workforce draws global companies as we continue to grow North Carolina into a worldwide hub for the biotechnology industry."
Galapagos and Gilead expand collaboration to advance T cell engager programme
Sanofi secures EU approval for Rezurock in chronic graft-versus-host disease
Delonix Bioworks launches Phase 1 trial of next-generation MenB OMV vaccine DX-104
Hengrui Pharma and Braveheart Bio report positive Phase 2 results for HRS/BHB-1893 in oHCM
Innovent and Ollin Biosciences report IBI324 study data in wAMD and DME
Fusion Antibodies signs GBP250,000 IP transfer deal with Finn Therapeutics
GSK's bepirovirsen accepted for review in China as potential Hepatitis B functional cure
4DMedical secures EU approval for CT:VQ as EUR83m funding fuels European expansion
Aurinia Pharmaceuticals agrees to acquire Kezar Life Sciences
Lunit and CellCarta partner to advance AI-driven digital pathology in CDx development